LIPG Genotype

If your HDL cholesterol has always run unusually high, or unusually low, you may be looking at the influence of a single gene that quietly shapes your lipid biology from birth. LIPG (the endothelial lipase gene) is one of the most powerful inherited factors known to influence how your body remodels HDL particles.

This test reads the version of LIPG you inherited. The result is fixed for life and offers a window into why your cholesterol numbers may look the way they do, and how that might interact with your physical activity, body composition, and risk for several diseases.

What LIPG Does in Your Body

The LIPG gene gives instructions to build a protein called endothelial lipase. This protein is a 500-amino-acid enzyme produced by the cells lining your blood vessels, as well as by certain immune cells (macrophages) and the liver. It is also strongly expressed in heart muscle and the placenta during pregnancy.

Endothelial lipase acts mainly as a phospholipase, an enzyme that snips the fatty components off HDL particles. By doing so, it speeds up the breakdown of HDL. It also works alongside another enzyme, lipoprotein lipase (LPL), to break down triglyceride-rich particles that carry fat through your bloodstream.

How LIPG Variants Shape HDL Cholesterol

Several inherited variants in LIPG turn the endothelial lipase enzyme down. Less activity means HDL particles get broken down more slowly, so they accumulate to higher levels in the blood. The clearest example is a rare loss-of-function variant called Asn396Ser. Carriers consistently show higher HDL cholesterol than non-carriers.

Common variants such as Thr111Ile (also written as 584C>T) and the promoter variant -384A>C have been linked to HDL cholesterol differences in some populations, though effects vary. Functional studies show that the Thr111Ile change itself does not impair lipase activity in the lab, so any population-level HDL associations may be driven by linkage with a nearby regulatory variant rather than by this coding change directly. In Finnish men, coding variation in LIPG was one of the strongest gene-based signals for detailed HDL subclass traits, especially phospholipids carried in medium-size HDL particles. Studies in Chinese Maonan, Han, and Japanese American populations have linked several LIPG variants to differences in HDL cholesterol, ApoA1 (the main protein in HDL), LDL cholesterol, ApoB (the protein on heart-disease-causing particles), and triglycerides.

Heart Disease Risk Is More Complicated Than HDL Alone

Here is where the LIPG story gets interesting. A large Mendelian randomization study found that carriers of the LIPG Asn396Ser variant had higher HDL cholesterol, but their risk of heart attack was no different from non-carriers (odds ratio 0.99, 95% confidence interval 0.88 to 1.11). In plain English, the inherited HDL boost did not translate into fewer heart attacks.

Findings on the common Thr111Ile variant are similarly split. A meta-analysis of 14 case-control studies concluded the variant played a protective role against coronary artery disease. But a prospective study pooling three independent cohorts (one Danish and two American) found no link between this variant and coronary heart disease risk, with a pooled estimate of 0.95 (95% confidence interval 0.85 to 1.06) per allele. In Han Chinese, the promoter variant -384A>C was tied to higher coronary artery disease risk, while the 584C/T variant was not.

This is not a paradox to leave unresolved. LIPG is a phenotype-shaping gene, not a simple risk gene. It changes how your HDL particles are remodeled and how triglyceride-rich particles get cleared. Whether those changes translate into less heart disease depends on what HDL is actually doing for you (its function, not just its concentration) and on the other ways the variant affects your lipoprotein system. A higher HDL number caused by slowed catabolism is not the same as a higher HDL number caused by a more functional particle. That distinction explains why LIPG variants can raise HDL on a lab report without lowering heart attack rates.

Effects Beyond the Heart

LIPG variants have been linked to outcomes outside the cardiovascular system. The rare Asn396Ser variant was associated with more depressive symptoms, more white-matter lesions on brain imaging, and higher Alzheimer's disease risk in a large population study. Higher plasma levels of the endothelial lipase protein have also been associated with increased breast cancer risk, particularly in premenopausal women and in Luminal A and HER2-negative tumor subtypes, in an observational study.

These associations are still being worked out, and the breast cancer data come from measuring the protein in blood, not from testing the gene directly. They are useful as context, not as a reason to act on this specific genotype result in isolation.

Why Lifestyle and Body Composition Matter

LIPG variants do not act alone. In a study of European adolescents, the beneficial alleles of three LIPG variants only translated into a better cardiovascular risk profile in physically active teens. Inactive carriers did not see the same benefit. A separate study found that body fat strongly modified the effect of HDL-related genetic risk scores, with LIPG among the genes driving these gene-by-BMI interactions. In Chinese minority populations, the 584C>T variant interacted with smoking to influence blood pressure.

What this means for you: a LIPG genotype is a starting point, not a fate. The same variant can produce different lipid and blood pressure outcomes depending on how you live.

Your Result Is Permanent

Unlike cholesterol or blood sugar, your LIPG genotype does not change. You inherited it at conception, and a test today will give the same result as a test 20 years from now. There is no value in retesting the genotype unless the lab method used was a screening assay (like a SNP chip) and you want a confirmatory test by a different method (such as Sanger sequencing) to rule out a technical error.

The actionable monitoring that follows from this test is on the lipid side, not the genetic side. If you carry a variant that affects HDL and triglyceride-rich particle handling, your routine cardiovascular workup matters more. A baseline standard lipid panel, an ApoB measurement, and an Lp(a) reading give you the modifiable companion data. From there, retest those lipid markers at least annually, and every 3 to 6 months if you are making meaningful lifestyle or medication changes.

When Results Can Be Misleading

• Variant panel coverage: the assay only detects the specific variants it is designed to read. A negative result does not rule out rare or undiscovered variants elsewhere in the LIPG gene.
• Ethnic-specific allele frequencies: some LIPG variants are common in one population and rare in another, so the practical meaning of a positive or negative result depends partly on your ancestry. Most published evidence comes from European, East Asian, and a few minority cohorts.
• Variants of uncertain significance: if an unexpected LIPG variant is reported, its clinical meaning may not yet be established. This is common for newer or research-grade assays.
• Direct-to-consumer versus clinical-grade reports: a 23andMe-style raw data export for a LIPG locus is not the same as a clinical-grade sequencing result. Discrepancies between consumer and clinical reports are common and should be confirmed before acting.

What to Do If Your Genotype Is Unexpected

An unexpected LIPG result is not a diagnosis. It is information that should change how aggressively you monitor and act on the lipid measurements that actually drive cardiovascular outcomes.

• Get a full lipid workup if you have not already: standard panel plus ApoB plus Lp(a). LIPG variants can shift HDL, LDL, ApoB, and triglycerides in different ways, so a complete picture matters.
• Add HDL particle measurement if available: NMR or advanced HDL fractionation may help interpret unusually high or low HDL caused by altered endothelial lipase activity, since particle counts and sizes carry information that a single HDL cholesterol number does not.
• Consider a lipidology or preventive cardiology consultation: especially if you also have a family history of premature heart disease or unusually high or low HDL.
• Discuss with biological relatives: parents, siblings, and children may share the variant. Their cardiovascular risk picture could benefit from earlier and more frequent lipid screening, even if they currently feel well.

Prevention, Not Reassurance

A LIPG variant that raises HDL can create a false sense of security. The traditional view that high HDL is automatically protective does not hold up for everyone, and genetically driven high HDL has not been shown to lower heart attack risk in large studies. Treat this test as one of several inputs into your cardiovascular plan, not as permission to take your foot off the gas. The standard playbook still applies: keep ApoB low, stay active, maintain a healthy body composition, and avoid smoking. Those interventions matter more, not less, when your genetics complicate the lipid picture.